

Representative Life Science Deals

- Over \$8.9 Billion in Commitments to more than 460 Companies since 2003
- Total New Debt & Equity Commitments of ~\$414.8 Million Q1 2019
- Total New Fundings of ~\$239.6 Million Q1 2019
- Over 1,000 Co-investments with Different VC & PE Firms in the Last 15 Years
- Over 150 Companies completed IPO or M&A Events since Inception



**\$35,000,000
Debt Commitment**

Invested in 2019
NASDAQ: CNST

**\$150,000,000
Debt Commitment**

Invested in 2018, 2019
NASDAQ: TCDA

**\$60,000,000
Debt Commitment**

Invested in 2019
NASDAQ: UROV

**\$55,000,000
Debt Commitment**
**\$2,000,000
Equity Commitment**

Invested in 2018

**\$50,000,000
Debt Commitment**

Invested in 2018
NASDAQ: MESO

**\$70,000,000
Debt Commitment**

Invested in 2018
NASDAQ: NBRV

**\$70,000,000
Debt Commitment**
**\$1,000,000
Equity Commitment**

Invested in 2014, 2015,
2016, 2017, 2018
NASDAQ: PRTK

**\$40,000,000
Debt Commitment**

Invested in 2018
NASDAQ: TRXC

**\$13,000,000
Debt Commitment**

Invested in 2018
NASDAQ: XFOR

**\$30,000,000
Debt Commitment**

Invested in 2011, 2013,
2015, 2017
NASDAQ: ACRX

**\$35,000,000
Debt Commitment**

Invested in 2017
NASDAQ: ATRS

**\$20,000,000
Debt Commitment**

Invested in 2017
NASDAQ: BOLD



\$55,000,000
Debt Commitment

Invested in 2017
NASDAQ: AXON



\$30,000,000
Debt Commitment

Invested in 2016, 2017
NASDAQ: BLCM



\$25,000,000
Debt Commitment

Invested in 2017
NASDAQ: CCXI



\$30,000,000
Debt Commitment
\$20,000,000
Prior Debt Commitment

Invested in 2011, 2012, 2017
NASDAQ: CNCE



\$30,000,000
Debt Commitment

Invested in 2017



\$40,000,000
Debt Commitment

Invested in 2017
NYSE: MYOV



\$30,000,000
Debt Commitment

Invested in 2017



\$15,000,000
Debt Commitment
\$1,000,000
Equity Commitment

Invested in 2014, 2015, 2016, 2017
NASDAQ: QTRX



\$20,000,000
Debt Commitment

Invested in 2017
NASDAQ: MITO



\$55,000,000
Debt Commitment
\$1,000,000
Equity Commitment

Invested in 2012, 2014, 2016
Acquired by Jazz Pharma in 2016



\$15,000,000
Debt Commitment

Invested in 2014, 2015
Acquired by Jazz Pharma in 2016



\$40,000,000
Debt Commitment
\$550,000
Equity Commitment

Invested in 2014, 2015
NASDAQ: DVAX



\$8,500,000
Debt Commitment
\$2,500,000
Equity Commitment

Invested in 2008, 2010,
2012, 2015



\$35,000,000
Debt Commitment

Invested in 2013, 2014, 2018
NASDAQ: QURE



\$45,000,000
Debt Commitment

Invested in 2013
Acquired by Pfizer in 2016



\$22,000,000
Debt Commitment

Invested in 2011
NASDAQ: RVNC

Boston Office

R. Bryan Jadot

Sr. Managing Director
617.314.9981
bjadot@htgc.com

Kristen Kosofsky

Sr. Managing Director
617.851.5416
kkosofsky@htgc.com

Janice Bourque

Managing Director
617.314.9992
jbourque@htgc.com

Michael Dutra

Principal
617.314.9989
mdutra@htgc.com

Palo Alto Office

Nimesh Shah

Managing Director
650.433.5548
nshah@htgc.com

Himani Bhalla

Principal
650.433.5581
hbhalla@htgc.com

Ana Petrovic

Vice President
650.600.5439
apetrovic@htgc.com

San Diego Office

Lake McGuire

Managing Director
517.304.0382
lmcguire@htgc.com